Market Closed -
Nasdaq
16:00:00 2024-06-21 EDT
|
5-day change
|
1st Jan Change
|
8.85
USD
|
-3.28%
|
|
-4.43%
|
-10.24%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,895
|
1,461
|
2,136
|
2,103
|
-
|
-
|
Enterprise Value (EV)
1 |
2,379
|
918.1
|
1,745
|
1,745
|
1,767
|
1,748
|
P/E ratio
|
-11.5
x
|
-5.67
x
|
-6.24
x
|
-5.38
x
|
-4.86
x
|
-8.28
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
284
x
|
36.7
x
|
47.9
x
|
35.7
x
|
33.4
x
|
13.9
x
|
EV / Revenue
|
234
x
|
23
x
|
39.2
x
|
29.7
x
|
28
x
|
11.5
x
|
EV / EBITDA
|
-13.6
x
|
-3.92
x
|
-5.36
x
|
-4.26
x
|
-3.49
x
|
-3.36
x
|
EV / FCF
|
-12
x
|
-7.61
x
|
-5.82
x
|
-5.61
x
|
-4.84
x
|
-7.91
x
|
FCF Yield
|
-8.34%
|
-13.1%
|
-17.2%
|
-17.8%
|
-20.7%
|
-12.6%
|
Price to Book
|
5.37
x
|
2.79
x
|
4.97
x
|
5.31
x
|
8.06
x
|
9.88
x
|
Nbr of stocks (in thousands)
|
168,993
|
189,556
|
216,623
|
237,664
|
-
|
-
|
Reference price
2 |
17.13
|
7.710
|
9.860
|
8.850
|
8.850
|
8.850
|
Announcement Date
|
22-03-23
|
23-02-27
|
24-02-27
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
3.962
|
10.18
|
39.84
|
44.58
|
58.86
|
63.02
|
151.4
|
EBITDA
1 |
-
|
-174.4
|
-234
|
-325.7
|
-409.7
|
-506.7
|
-520.5
|
EBIT
1 |
-
|
-182.8
|
-245.7
|
-350.1
|
-426
|
-508.4
|
-478.8
|
Operating Margin
|
-
|
-1,795.79%
|
-616.74%
|
-785.33%
|
-723.73%
|
-806.68%
|
-316.2%
|
Earnings before Tax (EBT)
1 |
-
|
-186.5
|
-239.5
|
-332.1
|
-392
|
-484
|
-347
|
Net income
1 |
-87.01
|
-186.5
|
-239.5
|
-328.1
|
-401.5
|
-472.5
|
-347.2
|
Net margin
|
-2,196.01%
|
-1,832.18%
|
-601.05%
|
-735.99%
|
-682.13%
|
-749.68%
|
-229.24%
|
EPS
2 |
-5.990
|
-1.490
|
-1.360
|
-1.580
|
-1.644
|
-1.820
|
-1.069
|
Free Cash Flow
1 |
-
|
-198.4
|
-120.6
|
-299.7
|
-311
|
-365
|
-221
|
FCF margin
|
-
|
-1,949.42%
|
-302.65%
|
-672.43%
|
-528.38%
|
-579.17%
|
-145.94%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-03-03
|
22-03-23
|
23-02-27
|
24-02-27
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
2.533
|
5.333
|
7.674
|
13.16
|
13.68
|
12.13
|
11.02
|
10.53
|
10.89
|
13.79
|
13.75
|
13.93
|
15.37
|
15.1
|
15.35
|
EBITDA
1 |
-
|
-
|
-
|
-59.58
|
-
|
-66.14
|
-76.17
|
-
|
-91.38
|
-
|
-89
|
-88.3
|
-182.1
|
-198.7
|
-202.7
|
EBIT
1 |
-64.96
|
-55.98
|
-66.19
|
-62.57
|
-60.98
|
-69.86
|
-81.72
|
-99.55
|
-98.93
|
-96.34
|
-102.4
|
-106.5
|
-130.6
|
-153.6
|
-155.5
|
Operating Margin
|
-2,564.55%
|
-1,049.71%
|
-862.54%
|
-475.48%
|
-445.91%
|
-575.78%
|
-741.72%
|
-945.12%
|
-908.36%
|
-698.42%
|
-744.57%
|
-764.26%
|
-849.67%
|
-1,016.89%
|
-1,013.03%
|
Earnings before Tax (EBT)
1 |
-64.93
|
-
|
-65.56
|
-60.44
|
-57.49
|
-65.33
|
-76.73
|
-93.02
|
-94.62
|
-92.15
|
-97
|
-98
|
-104
|
-
|
-
|
Net income
1 |
-64.93
|
-55.98
|
-65.56
|
-60.44
|
-57.49
|
-65.33
|
-76.73
|
-93.02
|
-93
|
-91.37
|
-96.9
|
-97.25
|
-123.6
|
-153.6
|
-155.6
|
Net margin
|
-2,563.48%
|
-1,049.67%
|
-854.31%
|
-459.31%
|
-420.39%
|
-538.38%
|
-696.43%
|
-883.1%
|
-853.88%
|
-662.41%
|
-704.73%
|
-697.97%
|
-804.5%
|
-1,017.22%
|
-1,013.68%
|
EPS
2 |
-0.3800
|
-0.3300
|
-0.3800
|
-0.3500
|
-0.3000
|
-0.3400
|
-0.3800
|
-0.4300
|
-0.4200
|
-0.3900
|
-0.3994
|
-0.3925
|
-0.4755
|
-0.6650
|
-0.6650
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
22-03-23
|
22-05-10
|
22-08-09
|
22-11-08
|
23-02-27
|
23-05-08
|
23-08-08
|
23-11-09
|
24-02-27
|
24-05-09
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
516
|
543
|
390
|
358
|
336
|
355
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-198
|
-121
|
-300
|
-311
|
-365
|
-221
|
ROE (net income / shareholders' equity)
|
-
|
-111%
|
-46.6%
|
-69.1%
|
-91.7%
|
-126%
|
-125%
|
ROA (Net income/ Total Assets)
|
-
|
-41%
|
-36.5%
|
-48.4%
|
-63.6%
|
-86.7%
|
-63.7%
|
Assets
1 |
-
|
454.5
|
655.8
|
677.5
|
631.8
|
544.8
|
545.1
|
Book Value Per Share
2 |
-
|
3.190
|
2.770
|
1.980
|
1.670
|
1.100
|
0.9000
|
Cash Flow per Share
2 |
-
|
-1.270
|
-0.4800
|
-1.380
|
-1.050
|
-0.6400
|
-
|
Capex
1 |
-
|
39.8
|
37.1
|
12
|
13
|
14
|
16
|
Capex / Sales
|
-
|
391.02%
|
93.01%
|
26.82%
|
22.09%
|
22.21%
|
10.57%
|
Announcement Date
|
21-03-03
|
22-03-23
|
23-02-27
|
24-02-27
|
-
|
-
|
-
|
Last Close Price
8.85
USD Average target price
13
USD Spread / Average Target +46.89% Consensus |
1st Jan change
|
Capi.
|
---|
| -10.24% | 2.1B | | +15.19% | 121B | | +19.91% | 114B | | +8.24% | 23.61B | | -19.80% | 20.43B | | -16.19% | 16.55B | | -13.45% | 16.45B | | -44.35% | 15.59B | | +66.67% | 15.19B | | +2.13% | 13.54B |
Bio Therapeutic Drugs
|